Edition:
India

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.62USD
19 Jan 2018
Change (% chg)

$-0.04 (-2.41%)
Prev Close
$1.66
Open
$1.65
Day's High
$1.66
Day's Low
$1.60
Volume
10,139
Avg. Vol
86,124
52-wk High
$4.68
52-wk Low
$1.35

Chart for

About

Imprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through... (more)
No analyst recommendations are available for .

Overall

Beta: -0.61
Market Cap(Mil.): $34.31
Shares Outstanding(Mil.): 20.07
Dividend: --
Yield (%): --

Financials

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

17 Jan 2018

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

15 Nov 2017

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

20 Oct 2017

BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1‍​

* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1‍​ Further company coverage:

19 Oct 2017

BRIEF-Imprimis Pharmaceuticals to offer compounded Cyclosporine alternative to Restasis

* Imprimis Pharmaceuticals-‍making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis​ Source text for Eikon: Further company coverage:

19 Oct 2017

BRIEF-FDA Curcumin Investigation supports Imprimis statement

* Imprimis Pharmaceuticals Inc - ‍provided an update regarding FDA Medwatch notice issued on August 4, 2017​

14 Sep 2017

BRIEF-Imprimis Pharmaceuticals ‍responded to Allergan Plc press release regarding lawsuit

* Imprimis Pharmaceuticals Inc - ‍responded to a press release issued by Allergan Plc regarding a lawsuit Allergan USA, Inc. filed against Imprimis​

11 Sep 2017

BRIEF-Allergan USA files suits against Imprimis, Prescriber's Choice and Sincerus Florida

* Allergan files suits against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC

08 Sep 2017

BRIEF-Imprimis Pharmaceuticals Q2 earnings per share $0.07

* Imprimis pharmaceuticals announces second quarter 2017 financial results

11 Aug 2017

BRIEF-Imprimis provides statement regarding curcumin emulsion FDA medwatch notice

* Imprimis statement regarding curcumin emulsion FDA medwatch notice

07 Aug 2017

Competitors

  Price Chg
Eli Lilly and Co (LLY.N) $85.49 -0.33
Sanofi SA (SASY.PA) €72.95 +0.58
Bayer AG (BAYGn.DE) €104.08 +0.60
Bayer AG (BAYE.F) -- --
Roche Holding Ltd. (ROG.S) CHF234.50 +1.30
Roche Holding Ltd. (RO.S) CHF237.80 +1.00
Merck & Co., Inc. (MRK.N) $61.28 +0.15
Novartis AG (NOVN.S) CHF83.38 +0.48

Earnings vs. Estimates